# Azurity Pharmaceuticals, Inc., Wilmington, MA – FDA Inspections

Source: https://www.keypedia.com/companies/azurity-pharmaceuticals-inc/be6c2042-21df-4e44-a30d-11c6629303d8

> Inspection records and compliance data for Azurity Pharmaceuticals, Inc. in Wilmington, Massachusetts. 9 FDA inspections on record, 2 Form 483s, last inspected December 12, 2025.

---

## Details

- Name: Azurity Pharmaceuticals, Inc.
- FEI Number: 3003395329
- Address Line 1: 841 Woburn St
- City: Wilmington
- State: Massachusetts
- Zip Code: 01887
- Country Name: United States
- Address: 841 Woburn St, Wilmington, Massachusetts 01887, United States
- Country: United States

## Related Documents

- FDA Inspection 1297348 - Azurity Pharmaceuticals, Inc. - 2025-12-12 — source: FDA, date: December 12, 2025
- [FDA Inspection 1297348 - Azurity Pharmaceuticals, Inc. - 2025-12-12](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/7c93bd99-060c-47b1-906c-ce6cdfe7bf52) — classification: No Action Indicated (NAI), source: FDA, date: December 12, 2025
- [483 - Azurity Pharmaceuticals, Inc. - 2025-02-19](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/fbd8eaca-fe0a-415e-8722-8c80ddd8f442) — source: FDA, date: February 19, 2025
- [FDA Inspection 1261303 - Azurity Pharmaceuticals, Inc. - 2025-02-19](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/5bc3e1cb-551b-4b19-8657-c5a1e0e2c087) — source: FDA, date: February 19, 2025
- [483 - Azurity Pharmaceuticals, Inc. - 2023-03-02](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/3a26f0be-61a2-41f0-9deb-51eead2d9a04) — source: FDA, date: March 2, 2023
- [FDA Inspection 1199279 - Azurity Pharmaceuticals, Inc. - 2023-03-02](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/d81f0586-7c5d-4396-a80e-766283dec67c) — source: FDA, date: March 2, 2023
- [483 - Azurity Pharmaceuticals, Inc. - 2022-02-24](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/2704437d-fff0-4d09-b5aa-59c63a5d39d3) — source: FDA, date: February 24, 2022
- [FDA Inspection 1163010 - Azurity Pharmaceuticals, Inc. - 2022-02-24](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/12a62341-3a2c-4ccd-af8a-ac1ef6bbb9ad) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 24, 2022
- [483 - Azurity Pharmaceuticals, Inc. - 2020-01-15](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/5112db17-449d-4ac7-802d-0dd69b3bd25b) — source: FDA, date: January 15, 2020
- [EIR - Azurity Pharmaceuticals, Inc. - 2019-12-22](https://www.keypedia.com/records/eir/azurity-pharmaceuticals-inc/d0036b3f-fbc3-465f-98b8-8381b746748d) — source: FDA, date: December 22, 2019
- FDA Inspection 1100022 - Azurity Pharmaceuticals, Inc. - 2019-07-26 — classification: No Action Indicated (NAI), source: FDA, date: July 26, 2019
- FDA Inspection 1038444 - Azurity Pharmaceuticals, Inc. - 2017-12-20 — source: FDA, date: December 20, 2017
- [EIR - Azurity Pharmaceuticals, Inc. - 2016-04-19](https://www.keypedia.com/records/eir/azurity-pharmaceuticals-inc/9a78ab74-7a67-4339-9e11-71498e3a5517) — source: FDA, date: April 19, 2016
- FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19 — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016
- FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19 — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016
- FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19 — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016

## Related Companies

- [Novo Nordisk Inc.](https://www.keypedia.com/companies/novo-nordisk-inc/920bb4ea-9450-45a6-bcd7-9f85c2f2bbad)
- [Anuj Bhargava MD](https://www.keypedia.com/companies/anuj-bhargava-md/ac19e638-a374-4571-851f-926c48498d28)
- [Jed C. Kaminetsky, M.D.](https://www.keypedia.com/companies/jed-c-kaminetsky-md/1fb748ee-6c96-4a54-a49f-11020b879afb)
- [Genlabs Corporation](https://www.keypedia.com/companies/genlabs-corporation/d064f8a7-2b33-40d0-b1c9-02465de0f974)
- [IQVIA](https://www.keypedia.com/companies/iqvia/baa6e561-8fc3-48db-8b19-844cbc9e9755)
- [Inotiv Inc](https://www.keypedia.com/companies/inotiv-inc/be017b67-b3f0-402d-8a03-b124ca114fa6)
- [Ferring Pharmaceuticals Inc](https://www.keypedia.com/companies/ferring-pharmaceuticals-inc/83aaeefd-d198-40f3-9192-71a8c408f5cf)
- [Pharmasol Corporation](https://www.keypedia.com/companies/pharmasol-corporation/7961d42d-8409-45eb-8448-c0f2729ef17c)
- [S&B Pharma LLC](https://www.keypedia.com/companies/sb-pharma-llc/232b2ea9-4ea7-41e2-aed7-7b885ca80003)
- [Boston University National Emerging Infectious Disease Laboratories](https://www.keypedia.com/companies/boston-university-national-emerging-infectious-disease-laboratories/050558e2-09bc-4c20-856b-d9bbdf2a9300)

## Related Officers

- [Arizona Market President](https://www.keypedia.com/people/john-p-mistler/7b2d423d-46cc-48bd-aa5a-4ae794888060)
- [Regulatory Officer I n ve s tig ato r ](https://www.keypedia.com/people/dien-nguyen/90e26f94-e417-4c64-ab44-3674387b82b4)
- [Principal](https://www.keypedia.com/people/christopher-janik/2803fa51-5259-4632-93ad-c6f038bd2fd4)
- [Investigator](https://www.keypedia.com/people/erik-w-koester/2bbab081-6783-40a1-83c1-b219bde22bd1)